Your browser is no longer supported. Please, upgrade your browser.
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.88 Insider Own0.40% Shs Outstand155.93M Perf Week4.28%
Market Cap17.70B Forward P/E- EPS next Y-1.05 Insider Trans-27.28% Shs Float155.60M Perf Month22.36%
Income-126.20M PEG- EPS next Q-0.56 Inst Own97.90% Short Float2.58% Perf Quarter23.01%
Sales667.10M P/S26.53 EPS this Y-34.70% Inst Trans1.63% Short Ratio3.10 Perf Half Y61.02%
Book/sh10.26 P/B11.06 EPS next Y46.00% ROA-5.40% Target Price118.74 Perf Year43.16%
Cash/sh4.27 P/C26.56 EPS next 5Y25.00% ROE-8.70% 52W Range55.04 - 116.70 Perf YTD25.55%
Dividend- P/FCF- EPS past 5Y-44.30% ROI-8.50% 52W High-0.92% Beta0.94
Dividend %- Quick Ratio4.20 Sales past 5Y13.10% Gross Margin83.70% 52W Low110.07% ATR3.72
Employees1341 Current Ratio5.20 Sales Q/Q29.10% Oper. Margin-23.30% RSI (14)78.21 Volatility3.05% 3.50%
OptionableYes Debt/Eq0.44 EPS Q/Q113.20% Profit Margin-18.90% Rel Volume1.23 Prev Close113.50
ShortableYes LT Debt/Eq0.44 EarningsFeb 25 AMC Payout- Avg Volume1.29M Price115.63
Recom1.80 SMA2011.87% SMA5017.71% SMA20048.55% Volume353,523 Change1.87%
Dec-19-14Reiterated RBC Capital Mkts Outperform $103 → $110
Dec-11-14Reiterated UBS Buy $87 → $112
Nov-25-14Reiterated RBC Capital Mkts Outperform $87 → $103
Oct-24-14Reiterated RBC Capital Mkts Outperform $77 → $87
Feb-19-14Reiterated Barclays Equal Weight $73 → $76
Jan-14-14Reiterated Deutsche Bank Buy $75 → $85
Jan-10-14Downgrade Barclays Overweight → Equal Weight $75 → $73
Oct-25-13Reiterated Barclays Overweight $70 → $75
Sep-18-13Downgrade Stifel Buy → Hold
Jul-26-13Reiterated Stifel Buy $67 → $70
Apr-03-13Reiterated Barclays Overweight $54 → $70
Mar-20-13Reiterated RBC Capital Mkts Outperform $58 → $64
Mar-20-13Reiterated Deutsche Bank Hold $45 → $59
Feb-22-13Reiterated RBC Capital Mkts Outperform $55 → $58
Feb-01-13Reiterated UBS Buy $53 → $67
Jan-22-13Upgrade Stifel Nicolaus Hold → Buy $67
Nov-06-12Reiterated Barclays Overweight $46 → $54
Nov-06-12Downgrade Brean Capital Buy → Hold
Sep-28-12Reiterated Summer Street Research Buy $45 → $52
Aug-27-12Downgrade Deutsche Bank Buy → Hold $40 → $45
Mar-06-15 08:20AM  The Next 3 Likely Biotech Buyout Candidates at 24/7 Wall St.
Mar-05-15 07:08PM  10-K for BioMarin Pharmaceutical, Inc. Company Spotlight
06:13PM  Cramer: This X factor is ignored in your portfolio at CNBC
04:02PM  Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst Benzinga
Mar-03-15 10:09AM  BioMarin Pharmaceutical Inc. (BMRN) and Other Top New Picks of Healthcare-Focused Visium Asset Management at Insider Monkey
Feb-27-15 10:10AM  Company News for February 27, 2015 - Corporate Summary Zacks
09:30AM  Cowen Raises Price Targets on Top Momentum Stocks at 24/7 Wall St.
Feb-26-15 11:50AM  Actavis' Infectious Disease Product, Avycaz, Gets FDA Nod - Analyst Blog Zacks
11:20AM  Amgen Reports Encouraging Late-Stage Data on AMG 416 - Analyst Blog Zacks
10:20AM  Medivation Beats on Q4 Earnings & Revenues; Xtandi Soars - Analyst Blog Zacks
09:56AM  Merge Healthcare (MRGE) Q4 Earnings Up Y/Y; Revenues Miss - Analyst Blog Zacks
09:50AM  BioMarin's Q4 Loss Narrower than Expected, Gives 2015 View - Analyst Blog Zacks
09:30AM  Orexigen (OREX) Misses Q4 Earnings, Contrave Impresses - Analyst Blog Zacks
Feb-25-15 07:29PM  Lightning Round: This group goes higher tomorrow at CNBC
04:46PM  BioMarin reports 4Q loss AP
04:30PM  Biomarin Pharmaceutical Inc Earnings Call scheduled for 4:30 pm ET today CCBN
04:20PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
04:01PM  BioMarin Announces Fourth Quarter and Full Year 2014 Financial Results GlobeNewswire
11:47AM  PTC Therapeutics for Sale? Only to a Foolish, Risk-Blind Buyer at TheStreet
09:32AM  Alkermes Falls on Pipeline News; Q4 Earnings Plunge Y/Y - Analyst Blog Zacks
07:07AM  Q4 2014 Biomarin Pharmaceutical Inc Earnings Release - After Market Close CCBN
Feb-24-15 06:51PM  Illumina Expands NGS Portfolio with NeoPrep Library System - Analyst Blog Zacks
06:24PM  Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog Zacks
Feb-23-15 07:02PM  Cramer Remix: Where's the Nasdaq bubble? at CNBC
06:50PM  Lightning Round: Don't listen to this CEO at CNBC
06:20PM  Celgene Gains on Label Expansion of Revlimid in the EU - Analyst Blog Zacks
04:20PM  Will BioMarin (BMRN) Beat Estimates this Earnings Season? - Analyst Blog Zacks
Feb-20-15 04:15PM  BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
02:30PM  Celgene Up on Hematology Drug Revlimid's Label Expansion - Analyst Blog Zacks
Feb-19-15 06:24PM  Regeneron's Eylea Tops Diabetic Macular Edema Study - Analyst Blog Zacks
05:10PM  Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris - Analyst Blog Zacks
12:20PM  Coronado Biosciences In-Licenses Revogenex's Pain Drug - Analyst Blog Zacks
Feb-18-15 05:50PM  Seattle Genetics' SEA-CD40 Enters Phase I for Solid Tumors - Analyst Blog Zacks
04:08PM  Oncolytics' Reolysin Gets Another Orphan Drug Status - Analyst Blog Zacks
Feb-17-15 09:20AM  Actelion's (ALIOF) Earnings & Revenues Fall Y/Y in Q4 - Analyst Blog Zacks
09:11AM  Synthetic Biologics (SYN) Jumps: Stock Up 9.2% - Tale of the Tape Zacks
Feb-16-15 04:40PM  AstraZeneca's Patent for Pulmicort Respules Found Invalid - Analyst Blog Zacks
04:10PM  Emergent BioSolutions Reports Positive Data on BioThrax - Analyst Blog Zacks
Feb-13-15 09:26AM  Acorda Beats Q4 Earnings Estimates; Ampyra Sales Grow - Analyst Blog Zacks
Feb-12-15 04:10PM  Amgen's Skin Cancer Drug to Face FDA Advisory Panel - Analyst Blog Zacks
12:40PM  Oncolytics' Reolysin Gets Orphan Status for Ovarian Cancer - Analyst Blog Zacks
Feb-11-15 02:42PM  Isis Pharma to Get $5M from Biogen - Analyst Blog Zacks
01:30PM  Synthetic Biologics Unveils Phase Ib Safety Data on SYN-004 - Analyst Blog Zacks
10:06AM  Genomic Health Loss Narrower than Expected, Revenues Lag - Analyst Blog Zacks
09:18AM  Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog Zacks
Feb-10-15 04:38PM  Regeneron Earnings Growth Falls Short, But Eylea Sales, '15 Outlook Are Solid Investor's Business Daily
12:16PM  Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution GlobeNewswire
11:01AM  Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea at Investor's Business Daily
Feb-09-15 02:43PM  Analyst Sees BioMarin Up Another 25% at 24/7 Wall St.
08:00AM  BioMarin Announces 2 Oral and 8 Poster Presentations at Lysosomal Disease Network's 11th Annual WORLD Symposium(TM) GlobeNewswire
Feb-04-15 08:00AM  BioMarin to Attend Upcoming Investor Conferences GlobeNewswire
Feb-03-15 08:00AM  BioMarin to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Wednesday, February 25 at 4:30pm ET GlobeNewswire
Jan-30-15 08:13AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Stateme EDGAR Online
08:00AM  BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period GlobeNewswire
Jan-29-15 02:27PM  When does the biotech party end? at CNBC
Jan-28-15 06:25PM  Synageva Starts Dosing in Phase I/II Study for Sanfilippo B - Analyst Blog Zacks
Jan-27-15 07:30AM  Rare feat: BioMarin rewrites playbook for small-market drug approvals at American City Business Journals
06:00AM  Jim Cramer's Top Stock Picks: BMRN HSY KMB at TheStreet
Jan-26-15 08:22PM  Jim Cramer's 'Mad Money' Recap: 8 Ways to Tell a Healthy Market From a Sick One at TheStreet
Jan-24-15 06:00AM  'Mad Money' Lightning Round: Constellation Brands the New King in Town at TheStreet
Jan-23-15 07:36PM  Lightning Round: These stocks bottomed last week at CNBC
04:55PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S EDGAR Online
08:00AM  BioMarin Announces Underwriters' Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Jan-22-15 06:00PM  BioMarin to Raise Funds to Finance Prosensa Acquisition - Analyst Blog Zacks
07:56AM  Money. Biotech. More Money. Biotech. Lots of Money. Biotech. Yahoo Finance Contributors
12:40AM  BioMarin Announces Pricing of Public Offering of Common Stock GlobeNewswire
Jan-21-15 04:01PM  BioMarin Announces Public Offering of Common Stock GlobeNewswire
06:25AM  State Of The Union Lights Up Biotech Benzinga
05:00AM  Losing to win, in pro basketball and business at Fortune
Jan-16-15 07:00PM  Cramer Executive Cut: Transportation & biotech CNBC
03:34PM  Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical Benzinga
06:01AM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition EDGAR Online
06:00AM  Jim Cramer's Top Stock Picks: NVAX TGT BMRN RCPT at TheStreet
Jan-15-15 08:01PM  Jim Cramer's 'Mad Money' Recap: 5 Reasons Why You Must Buy American Stocks at TheStreet
06:42PM  Cramer's top biotech has enormous value creation at CNBC
06:35PM  BioMarin CEO: Vimizim launch better than anticipated CNBC
01:10PM  Biotech Rivalry Gets Nasty in Mudslinging Battle Over Trial Data at Bloomberg
08:00AM  BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period GlobeNewswire
Jan-14-15 05:10PM  BioMarin Gains on Vimizim 2014 View, Batten Disease Data - Analyst Blog Zacks
07:08AM  UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical On Positive Preliminary BMN-190 Data Benzinga
Jan-12-15 02:38PM  BioMarin Shows Up Rival Sarepta During 'JPM15' Investor Presentation at TheStreet
01:45PM  BioMarin Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study of BMN 190 for Treatment of CLN2 Disorder, a Form of Batten Disease GlobeNewswire
09:47AM  Sarepta Updates Eteplirsen Study Results, FDA Filing Still on for Mid Year at TheStreet
Jan-09-15 03:42PM  Regeneron Jumps On Favorable Cholesterol Drug Report at Investor's Business Daily
Jan-08-15 04:44PM  Thursday's Market Recap Yahoo Finance Blogs
Jan-07-15 04:15PM  BioMarin Announces Planned Changes to Board of Directors Leadership Structure GlobeNewswire
Jan-06-15 08:00AM  BioMarin to Present at the J.P. Morgan Healthcare Conference GlobeNewswire
Dec-29-14 08:00AM  BioMarin Announces Approval of VIMIZIM(R) (elosulfase alfa) in Japan for Treatment of Morquio A Syndrome GlobeNewswire
Dec-24-14 01:15PM  BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa GlobeNewswire
Dec-23-14 05:24PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online -5.94%
04:11PM  BioMarin CEO Sees Big Future For Prosensa Drug at Investor's Business Daily
Dec-22-14 08:23AM  J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015 at TheStreet
Dec-12-14 12:40PM  PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout PR Newswire
Dec-10-14 12:32PM  BIOMARIN PHARMACEUTICAL INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement EDGAR Online
08:01AM  BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome GlobeNewswire
08:00AM  FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B) GlobeNewswire
Dec-09-14 08:00AM  BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York GlobeNewswire
Dec-07-14 04:00PM  BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome GlobeNewswire
Dec-05-14 06:00AM  Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta at TheStreet
Dec-03-14 05:24PM  Rare disease biotech deal CNBC
BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAFFI ROBERTEVP, Technical OperationsMar 05Option Exercise17.1114,051240,364123,751Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Option Exercise12.9910,000129,90052,279Mar 05 08:20 PM
BAFFI ROBERTEVP, Technical OperationsMar 05Sale116.3714,0511,635,091109,700Mar 05 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 05Sale113.7010,0001,137,01642,279Mar 05 08:20 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Option Exercise9.865004,93043,695Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 04Sale107.7191698,66042,279Mar 04 07:39 PM
LAPALME PIERREDirectorMar 03Option Exercise14.2420,000284,80050,150Mar 05 05:34 PM
Mueller BrianVP, Corporate ControllerMar 03Option Exercise28.237,000197,61015,800Mar 05 05:31 PM
Mueller BrianVP, Corporate ControllerMar 03Sale109.467,000766,2108,800Mar 05 05:31 PM
LAPALME PIERREDirectorMar 03Sale106.5720,0002,131,40030,150Mar 05 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 03Sale107.425,000537,097215,157Mar 04 07:39 PM
Davis George EricSVP, General CounselMar 02Option Exercise26.4923,000609,27087,246Mar 04 07:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Option Exercise12.993,00038,97046,195Mar 04 07:39 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Option Exercise39.0615,500605,43084,176Mar 04 07:48 PM
Davis George EricSVP, General CounselMar 02Sale108.3123,0002,491,02764,246Mar 04 07:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 02Sale107.0015,5001,658,50068,676Mar 04 07:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale107.963,000323,89343,195Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 02Sale108.445,000542,195220,157Mar 04 07:39 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 09Sale94.142,000188,286225,157Jan 13 07:38 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Option Exercise12.993,00038,97046,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.733,000266,19343,195Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 24Sale88.732,000177,462227,157Dec 29 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Option Exercise12.992,00025,98045,195Dec 12 01:51 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 10Sale95.002,000190,00043,195Dec 12 01:51 PM
LEWIS ALANDirectorDec 04Option Exercise21.517,500161,32528,900Dec 08 06:50 PM
LEWIS ALANDirectorDec 04Sale89.907,500674,22521,400Dec 08 06:50 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Option Exercise38.5912,000463,08043,590Dec 05 05:26 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfDec 03Sale91.0112,0001,092,16131,590Dec 05 05:26 PM
Mueller BrianVP, Corporate ControllerDec 02Option Exercise28.235,000141,1509,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 02Sale91.825,000459,1004,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Option Exercise20.986,950145,78511,543Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerDec 01Sale90.256,950627,2384,593Dec 03 05:46 PM
Mueller BrianVP, Corporate ControllerNov 26Sale88.973,400302,5084,593Dec 02 05:19 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Option Exercise12.992,00025,98045,195Nov 28 09:24 PM
Davis George EricSVP, General CounselNov 25Option Exercise26.4920,000529,80084,426Nov 28 09:26 PM
Davis George EricSVP, General CounselNov 25Sale89.7520,0001,795,00064,426Nov 28 09:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 25Sale90.002,000180,00043,195Nov 28 09:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 12Sale81.511,00081,513228,157Nov 14 02:58 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Option Exercise21.5120,000430,20096,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Option Exercise12.994,00051,96047,195Nov 12 07:07 PM
FUCHS HENRY JEVP, Chief Medical OfficerNov 10Sale86.5520,0001,730,98276,550Nov 12 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 10Sale87.004,000348,00043,195Nov 12 07:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 03Sale85.333,000256,00243,195Nov 05 07:45 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfNov 03Sale83.54473,92631,590Nov 05 07:44 PM
BAFFI ROBERTEVP, Technical OperationsOct 30Option Exercise38.5929,9631,156,272129,163Oct 31 02:58 PM
Davis George EricSVP, General CounselOct 30Option Exercise26.4915,000397,35079,426Nov 03 07:21 PM
Davis George EricSVP, General CounselOct 30Sale83.2015,0001,247,93064,426Nov 03 07:21 PM
BAFFI ROBERTEVP, Technical OperationsOct 29Option Exercise33.7445,4621,533,721144,662Oct 31 02:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Option Exercise12.992,00025,98048,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Sale80.002,000160,00046,195Oct 28 07:09 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Option Exercise12.992,00025,98048,195Oct 23 06:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 21Sale75.002,000150,00046,195Oct 23 06:34 PM
Davis George EricSVP, General CounselSep 19Option Exercise21.5117,536377,19981,962Sep 23 08:41 PM
Davis George EricSVP, General CounselSep 19Sale69.7517,5361,223,13664,426Sep 23 08:41 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 03Sale69.77181,25668,733Feb 10 12:57 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Option Exercise39.0616,000624,96084,676Sep 03 06:48 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerSep 02Sale69.8316,0001,117,31468,676Sep 03 06:48 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Option Exercise12.995,00064,95051,195Aug 22 08:10 PM
BIENAIME JEAN JACQUESChief Executive OfficerAug 20Sale70.005,000350,00046,195Aug 22 08:10 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Option Exercise21.5110,000215,10086,550Aug 07 06:28 PM
FUCHS HENRY JEVP, Chief Medical OfficerAug 05Sale65.0010,000650,00076,550Aug 07 06:28 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerAug 01Sale61.762,229137,65268,676Aug 04 04:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 04Sale62.521,00062,521178,257Jun 05 07:33 PM
BIENAIME JEAN JACQUESChief Executive OfficerJun 03Sale59.881,00059,876179,257Jun 05 07:33 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfJun 02Sale57.8337721,80420,190Jun 03 06:54 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 22Sale56.881,00056,87646,195May 23 12:57 PM
BIENAIME JEAN JACQUESChief Executive OfficerMay 21Sale56.191,54586,81747,195May 22 06:27 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 16Sale56.861,864105,99460,950May 19 06:28 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 16Sale56.911,00457,13620,980May 19 06:27 PM
LAWLIS V BRYANDirectorMay 16Sale56.871,70096,6729,700May 19 06:31 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 13Sale58.231,43483,49864,850May 14 07:58 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 13Sale58.1847827,80923,080May 14 07:20 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 09Sale57.913,479201,47467,850May 12 04:46 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 09Sale57.9662135,99224,080May 13 04:44 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMay 02Sale58.571164468,737Feb 10 12:57 PM
FUCHS HENRY JEVP, Chief Medical OfficerMay 01Sale59.6771542,66673,850May 05 08:06 PM
Ajer Jeffrey RobertSVP, Chief Commercial OfMay 01Sale59.5566639,66125,380May 05 04:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 28Option Exercise12.992,00025,98048,740Apr 01 07:41 PM